V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220006658 | 220002561 | null | 52.1 | Curative (C) | 2014-08-12 | 2014-08-18 | AML MyeChild 01 A Mitozantrone/Cytarabine + GO | N | N | 220030754 | NOT MATCHED |
| 220006659 | 220002562 | null | 63.5 | Curative (C) | 2015-04-27 | 2015-04-27 | AML 19 TRIAL | N | N | 220030755 | AML19 TRIAL |
| 220006660 | 220002563 | 1.57 | 30.45 | Curative (C) | 2017-01-16 | 2017-01-16 | AML MyeChild 01 IT Cyt | 1 | N | 220030759 | NOT MATCHED |
| 220006661 | 220002563 | null | null | Curative (C) | 2015-09-29 | 2015-09-30 | Nilotinib | 2 | N | 220030759 | NILOTINIB |
| 220006664 | 220020382 | 1.72 | null | Curative (C) | 2014-08-26 | 2014-08-28 | Nilotinib | N | N | 220030764 | NILOTINIB |
| 220006665 | 220021259 | 1.72 | 66.2 | Curative (C) | 2013-05-10 | 2013-05-19 | AML 19 TRIAL | Y | N | 220030766 | AML19 TRIAL |
| 220006666 | 220021259 | 1.03 | 77 | Curative (C) | 2016-10-10 | 2016-10-10 | AML MyeChild 01 A Mitozantrone/Cytarabine + GO | N | N | 220030766 | NOT MATCHED |
| 220006667 | 220021259 | 1.64 | null | Disease modification (D) | 2016-03-02 | 2016-03-02 | Nilotinib | N | N | 220030766 | NILOTINIB |
| 220006668 | 220002564 | 0 | 0 | Radical (R) | 2017-03-17 | 2017-03-18 | Nilotinib | N | N | 220030775 | NILOTINIB |
| 220006669 | 220002564 | 1.83 | 58.3 | Curative (C) | 2015-08-03 | 2015-08-03 | AML 19 TRIAL | 1 | N | 220030775 | AML19 TRIAL |
| 220006670 | 220016175 | 0 | null | Unknown (U) | 2014-12-19 | 2014-12-19 | Nilotinib | 2 | N | 220030778 | NILOTINIB |
| 220006671 | 220016175 | null | 81.9 | Curative (C) | 2015-08-11 | 2015-08-14 | AML 19 TRIAL | 01 | Y | 220030778 | AML19 TRIAL |
| 220006672 | 220016175 | null | 67 | Curative (C) | 2017-07-30 | 2017-08-08 | FLAG + Idarubicin | N | N | 220030778 | FLAG + IDARUBICIN |
| 220006673 | 220002565 | 0 | 46.2 | Curative (C) | 2016-01-04 | 2016-01-04 | ALL Ph+ve Imatinib - Int Maint | N | N | 220030782 | NOT MATCHED |
| 220006674 | 220002566 | 1.74 | 107 | Curative (C) | 2015-03-11 | 2015-03-11 | AML 19 TRIAL | Y | N | 220030783 | AML19 TRIAL |
| 220006675 | 220002566 | 1.51 | 51.1 | Disease modification (D) | 2017-02-25 | 2017-03-30 | FLAG + Idarubicin | null | null | 220030783 | FLAG + IDARUBICIN |
| 220006676 | 220002567 | 1.79 | null | Curative (C) | 2015-09-20 | 2015-09-23 | AML MyeChild 01 A Mitozantrone/Cytarabine + GO | N | N | 220030785 | NOT MATCHED |
| 220006677 | 220002568 | 1.75 | 5.8 | Curative (C) | 2013-04-25 | 2013-04-25 | AML Relapsed FLA - Idarubicin | N | N | 220030791 | NOT MATCHED |
| 220006679 | 220011483 | null | null | Palliative (P) | 2014-07-11 | 2014-07-11 | Nilotinib | N | N | 220030798 | NILOTINIB |
| 220006680 | 220002570 | 1.83 | 77.5 | Curative (C) | 2016-06-10 | 2016-06-10 | AML 19 TRIAL | 1 | N | 220030801 | AML19 TRIAL |
| 220006681 | 220011484 | 1.55 | 56.8 | Curative (C) | null | 2014-07-25 | AML 19 TRIAL | Y | N | 220030802 | AML19 TRIAL |
| 220006682 | 220002571 | 1.8 | 118 | Curative (C) | 2016-01-06 | 2016-01-07 | AML 19 TRIAL | Y | N | 220030803 | AML19 TRIAL |
| 220006683 | 220011485 | 0 | 0 | Palliative (P) | null | 2014-04-11 | Nilotinib | 2 | N | 220030807 | NILOTINIB |
| 220006684 | 220011485 | null | null | Curative (C) | 2015-08-19 | 2015-08-22 | Nilotinib | N | N | 220030807 | NILOTINIB |
| 220006685 | 220011485 | 1.6 | 54.8 | Curative (C) | 2017-02-22 | 2017-02-27 | FLAG + Idarubicin | N | N | 220030807 | FLAG + IDARUBICIN |
| 220006686 | 220011485 | 0 | null | Curative (C) | 2014-09-02 | 2014-09-03 | Nilotinib | 02 | null | 220030807 | NILOTINIB |
| 220006687 | 220002572 | 1.8 | 57.8 | Curative (C) | 2017-02-18 | 2017-02-20 | AML 19 TRIAL | 01 | N | 220030811 | AML19 TRIAL |
| 220006688 | 220002573 | 1.78 | 12.2 | Palliative (P) | 2015-11-02 | 2016-04-09 | AML MyeChild 01 A Mitozantrone/Cytarabine | N | N | 220030813 | NOT MATCHED |
| 220006689 | 220002573 | 1.6 | 68 | Curative (C) | 2016-12-24 | 2017-03-06 | FLAG + Idarubicin | null | null | 220030813 | FLAG + IDARUBICIN |
| 220006690 | 220002573 | 0 | 78.3 | Curative (C) | 2016-03-22 | 2016-03-26 | Nilotinib | 2 | N | 220030813 | NILOTINIB |
| 220006691 | 220002573 | 0 | null | Curative (C) | 2016-05-24 | 2016-05-24 | Nilotinib | N | N | 220030813 | NILOTINIB |
| 220006692 | 220002573 | 1.64 | 86.1 | Curative (C) | 2014-08-15 | 2014-08-28 | AML 19 TRIAL | Y | N | 220030813 | AML19 TRIAL |
| 220006693 | 220002573 | 1.78 | 77.4 | Curative (C) | 2016-11-20 | 2016-11-23 | AML 19 TRIAL | 1 | N | 220030813 | AML19 TRIAL |
| 220006694 | 220002574 | 1.75 | null | null | 2013-07-15 | 2013-07-15 | Nilotinib | 2 | N | 220030823 | NILOTINIB |
| 220006695 | 220002575 | 1.68 | 60.8 | Curative (C) | 2017-09-14 | 2017-09-14 | AML 19 TRIAL | 1 | N | 220030825 | AML19 TRIAL |
| 220006696 | 220002575 | 1.73 | 52.1 | Curative (C) | 2017-05-21 | 2017-06-12 | AML Interim Guidelines | N | N | 220030825 | NOT MATCHED |
| 220006697 | 220002576 | 1.66 | 68 | Curative (C) | 2014-09-26 | 2014-09-28 | FLAG + Idarubicin | 01 | N | 220030827 | FLAG + IDARUBICIN |
| 220006700 | 220002577 | 0 | 78.9 | Disease modification (D) | 2016-11-23 | 2016-12-03 | Nilotinib | N | N | 220030838 | NILOTINIB |
| 220006701 | 220011489 | 1.64 | 60.6 | Curative (C) | 2016-03-25 | 2016-03-25 | AML 19 TRIAL | 01 | N | 220030840 | AML19 TRIAL |
| 220006702 | 220011489 | 1.75 | 76.7 | Curative (C) | 2017-06-17 | 2017-06-18 | AML 19 TRIAL | Y | N | 220030840 | AML19 TRIAL |
| 220006703 | 220002578 | null | null | Disease modification (D) | 2018-04-20 | 2018-04-25 | Nilotinib | N | N | 220030847 | NILOTINIB |
| 220006704 | 220002579 | null | null | Disease modification (D) | 2013-06-28 | 2013-07-02 | Nilotinib | N | N | 220030849 | NILOTINIB |
| 220006705 | 220002579 | 1.66 | null | Palliative (P) | 2018-05-01 | 2018-07-20 | Nilotinib | 2 | N | 220030849 | NILOTINIB |
| 220006706 | 220002580 | 1.68 | 53.15 | Curative (C) | 2017-02-03 | 2017-02-03 | AML 19 TRIAL | Y | N | 220030858 | AML19 TRIAL |
| 220006707 | 220002580 | null | null | Curative (C) | 2016-07-24 | 2016-07-24 | Nilotinib | N | N | 220030858 | NILOTINIB |
| 220006708 | 220002580 | null | null | Disease modification (D) | 2016-07-03 | 2016-07-03 | Nilotinib | 2 | N | 220030858 | NILOTINIB |
| 220006709 | 220002580 | 1.79 | 0 | Palliative (P) | 2017-04-25 | 2017-04-29 | Nilotinib | N | N | 220030858 | NILOTINIB |
| 220006710 | 220002580 | null | null | Disease modification (D) | 2015-03-27 | 2015-03-30 | Nilotinib | N | N | 220030858 | NILOTINIB |
| 220006711 | 220002580 | 1.5 | 77 | Curative (C) | 2017-04-16 | 2017-04-16 | AML 19 TRIAL | Y | N | 220030858 | AML19 TRIAL |
| 220006712 | 220002580 | 1.5 | 118.9 | Curative (C) | 2014-12-02 | 2014-12-05 | AML 19 TRIAL | Y | N | 220030858 | AML19 TRIAL |